Enhancing clozapine management through finger prick testing
21 октября 2026 г.
Clozapine is an important treatment option for patients with treatment-resistant schizophrenia (TRS), but its use requires regular monitoring of neutrophil counts.
On 21 October, we explored the role of point-of-care testing (POCT) in clozapine monitoring and how finger-prick testing may help improve patient adherence and treatment compliance.
Hannah Nauhaus, Global Product Manager, discussed the usability of the HemoCue WBC DIFF System in psychiatric care settings.
The webinar also featured a recorded presentation by Professor Jimmi Nielsen, Senior Consultant at the Department of Psychiatry, Glostrup Hospital, Denmark, and Professor at the University of Copenhagen. Professor Nielsen shared insights into clozapine management, clinical practice and the use of point-of-care blood monitoring.
If you missed the webinar, you can watch the recording Webinars - HemoCue.